Pyxis Oncology, Inc. Operating Expenses
Pyxis Oncology, Inc. (PYXS) reported Operating Expenses of $25.99 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- Pyxis Oncology, Inc. operating expenses for the quarter ending 2026-06-30 was $25.99M, a 15.15% increase year-over-year.
- Pyxis Oncology, Inc. operating expenses for the quarter ending 2026-03-31 was $24.36M, a 6.31% increase year-over-year.
- Pyxis Oncology, Inc. operating expenses for the quarter ending 2025-06-30 was $22.57M.
- Pyxis Oncology, Inc. operating expenses for the quarter ending 2025-03-31 was $22.91M.
- Pyxis Oncology, Inc. operating expenses for fiscal 2023 was $82.20M, a 33.43% decline from fiscal 2022.
- Pyxis Oncology, Inc. operating expenses for fiscal 2022 was $123.48M, a 77.12% increase from fiscal 2021.
- Pyxis Oncology, Inc. operating expenses for fiscal 2021 was $69.72M, a 440.69% increase from fiscal 2020.
- Pyxis Oncology, Inc. operating expenses for fiscal 2020 was $12.89M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $25.99M 10-Q · filed 2026-08-13 | $50.35M 10-Q · filed 2026-08-13 | ||
| 2026-03-31 | $24.36M 10-Q · filed 2026-05-14 | |||
| 2025-06-30 | $22.57M 10-Q · filed 2026-08-13 | $45.48M 10-Q · filed 2026-08-13 | ||
| 2025-03-31 | $22.91M 10-Q · filed 2026-05-14 | |||
| 2023-12-31 | $17.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $43.12M derived: sum of 2 quarters · filed 2024-03-21 | $61.24M derived: sum of 3 quarters · filed 2024-03-21 | $82.20M 10-K · filed 2024-03-21 |
| 2023-09-30 | $25.35M 10-Q · filed 2023-11-07 | $43.48M derived: sum of 2 quarters · filed 2023-11-07 | $64.43M 10-Q · filed 2023-11-07 | $102.40M derived: sum of 4 quarters · filed 2024-03-21 |
| 2023-06-30 | $18.12M 10-Q · filed 2023-08-11 | $39.08M 10-Q · filed 2023-08-11 | $77.05M derived: sum of 3 quarters · filed 2024-03-21 | $105.44M derived: sum of 4 quarters · filed 2024-03-21 |
| 2023-03-31 | $20.95M 10-Q · filed 2023-05-11 | $58.93M derived: sum of 2 quarters · filed 2024-03-21 | $87.32M derived: sum of 3 quarters · filed 2024-03-21 | $113.05M derived: sum of 4 quarters · filed 2024-03-21 |
| 2022-12-31 | $37.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $66.37M derived: sum of 2 quarters · filed 2024-03-21 | $92.09M derived: sum of 3 quarters · filed 2024-03-21 | $123.48M 10-K · filed 2024-03-21 |
| 2022-09-30 | $28.39M 10-Q · filed 2023-11-07 | $54.12M derived: sum of 2 quarters · filed 2023-11-07 | $85.51M 10-Q · filed 2023-11-07 | $101.93M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $25.73M 10-Q · filed 2023-08-11 | $57.12M 10-Q · filed 2023-08-11 | $73.54M derived: sum of 3 quarters · filed 2023-08-11 | $85.16M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $31.39M 10-Q · filed 2023-05-11 | $47.81M derived: sum of 2 quarters · filed 2023-05-11 | $59.44M derived: sum of 3 quarters · filed 2023-05-11 | $65.38M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $16.43M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $28.05M derived: sum of 2 quarters · filed 2023-03-22 | $33.99M derived: sum of 3 quarters · filed 2023-03-22 | $69.72M 10-K · filed 2023-03-22 |
| 2021-09-30 | $11.62M 10-Q · filed 2022-11-01 | $17.56M derived: sum of 2 quarters · filed 2022-11-01 | $53.29M 10-Q · filed 2022-11-01 | $57.87M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $5.94M 10-Q · filed 2022-08-15 | $41.67M 10-Q · filed 2022-08-15 | $46.25M derived: sum of 3 quarters · filed 2022-08-15 | $49.44M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $35.73M 10-Q · filed 2022-05-13 | $40.31M derived: sum of 2 quarters · filed 2022-05-13 | $43.50M derived: sum of 3 quarters · filed 2022-05-13 | |
| 2020-12-31 | $4.58M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $7.77M derived: sum of 2 quarters · filed 2022-03-29 | $12.89M 10-K · filed 2022-03-29 | |
| 2020-09-30 | $3.19M 10-Q · filed 2021-11-15 | $8.31M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |